We look forward to seeing you at the following events in 2013. Check back regularly for updates on medical meetings, new podcasts, webinars and more.
ISHLT 33rd Annual Meeting - April 24-27, 2013; Montreal, Canada
AATS 93rd Annual Meeting - May 4-8, 2013; Minneapolis, MNSee all upcoming events
CorMatrix® Cardiovascular, Inc. is a privately held medical device company dedicated to developing and delivering innovative biomaterial devices that harness the body’s own innate ability to repair damaged heart tissue. The Company is currently researching, developing and commercializing a platform technology, known as CorMatrix ECM®, for a variety of cardiovascular indications.
Incorporated in December of 2001, CorMatrix was co-founded by David Camp, an entrepreneurial executive in the cardiovascular medical device field, and Robert G. Matheny, MD, a cardiothoracic surgeon and co-inventor on several patents related to extracellular matrix (ECM) technology. Dr. Matheny’s interest and experience with these unique materials began at Purdue University in the 1990’s while he was a private practice cardiac surgeon in Indianapolis. Realizing the potential of extracellular matrix materials for cardiovascular surgery, he further increased his study and preclinical work in matrix materials and tissue repair.
Two years after approaching David Camp with his vision and the potential of his research, the two founded CorMatrix. Beecher Lewis joined the company soon thereafter to assume day-to-day management and oversight. After licensing the rights from Purdue University to research, develop, manufacture and market naturally occurring extracellular matrix materials for cardiovascular applications, and subsequently entering into a cross-license agreement with Cook Biotech, the Company began its acceleration.
In 2005, the Company received its first FDA clearance and shifted its focus from development stage to an integrated research, development and commercial entity. With significant patent protection, the Company is poised to successfully expand its current line of products.
CorMatrix ECM Technology
CorMatrix ECM Technology is a platform innovation with multiple cardiovascular applications.
This naturally occurring extracellular matrix biomaterial supports native tissue repair by providing an interim bioscaffold, that enables a patient’s own cells to repopulate and repair damaged tissues.
Addressing Unmet Needs
CorMatrix ECM Technology allows surgeons to restore the native anatomy of cardiovascular tissue in need of repair. Serving as a superior alternative to synthetic or cross-linked materials, the implanted CorMatrix ECM is remodeled over time, leaving the patient with only restored tissue structure instead of scar or injured tissue that would normally be expected when synthetic or cross-linked materials are used.
CorMatrix currently has three FDA cleared products utilizing its platform ECM Technology. CorMatrix ECM for Pericardial Closure is available for the reconstruction and repair of the pericardium during cardiac surgery and CorMatrix ECM for Cardiac Tissue Repair is available for suture-line reinforcing, buttressing for soft tissue re-approximation, repair of cannulation sites and bleeding sites, and as an intracardiac patch for tissue repair of structural problems such as septal defects. CorMatrix ECM for Carotid Repair was cleared by FDA in July of 2011 and will be available to repair the carotid artery including patch closure following endarterectomy procedures.
Since its launch in 2006, CorMatrix ECM Technology has been used at more than 720 hospitals across the U.S. and has been implanted in nearly 70,000 cardiac procedures.
Ongoing and Future Research
CorMatrix is currently conducting a number of preclinical and clinical studies utilizing its ECM Technology for a variety of cardiovascular applications. An emulsified form of CorMatrix ECM is currently in preclinical testing to assess the impact the technology may have on reversing cardiac damage resulting from a heart attack or congestive heart failure and potentially improving overall heart function.
The Company is also further assessing the impact that CorMatrix ECM for Pericardial Closure may have on postoperative outcomes in patients following bypass surgery.